Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Long-Term Survival in Liver Transplant Patients With Coronary Artery Disease: A Multi-Institutional Study

Wray CL, Scovotti JC, Tobis J, Honda HM, Planinsic R, Walia A, Findlay J, Wagener G, Cywinski JB, Olmos A, Markovic D, Hughes C, Humar[...]

Psychological and emotional drivers of atherosclerotic cardiovascular disease: Screening the brain to protect the heart

Atmani K, Vaseghi M. Psychological and emotional drivers of atherosclerotic cardiovascular disease: Screening the brain to protect the heart. Trends Cardiovasc Med. 2025 Nov 4:S1050-1738(25)00145-8.[...]

Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience

Fusco F, Scognamiglio G, Dellborg M, Dehghani P, Jameson SM, Kay WA, Cramer JW, Vonder Muhll I, Krieger EV, Rodriguez FH, Burchill LJ, Nicolarsen J,[...]